Valere Ziske
Family · Scottsdale, AZNPI 1548691504
Payments from drug & device makers
Across 112 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$524
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$244
- Novo Nordisk$189
- AstraZeneca$130
- Pfizer$86
- Abbott$79
- plus $784 from 21 others
What the payments were for
- Food & beverage$2,038100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $524 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $244 |
| Novo Nordisk | 10 | $189 |
| AstraZeneca | 8 | $130 |
| Pfizer | 5 | $86 |
| Abbott | 3 | $79 |
| QOL Medical, LLC | 3 | $71 |
| Novartis | 3 | $66 |
| Biohaven Pharmaceuticals, Inc. | 4 | $66 |
| Nestle Healthcare Nutrition Inc. | 3 | $66 |
| Exact Sciences | 2 | $56 |
| Cleerly, Inc. | 1 | $54 |
| Astellas Pharma US Inc | 2 | $41 |
| Phadia US Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Amgen | 2 | $34 |
| Impel Pharmaceuticals LLC | 1 | $26 |
| Biogen | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Nalu Medical, Inc. | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| GSK | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
How this compares
$2,038 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 22 | $2,221 |
| Levothyroxine Sodium | 31 | $270 |
| Hydrochlorothiazide | 18 | $215 |
| Metoprolol Succinate | 12 | $169 |
| Oxycodone Hcl | 16 | $150 |
| Atorvastatin Calcium | 14 | $111 |
| Tramadol Hcl | 12 | $84 |
| Rosuvastatin Calcium | 12 | $65 |
| Losartan Potassium | 15 | $52 |
| Lisinopril | 19 | $36 |
| Levocetirizine Dihydrochloride | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $524 | $2,22122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.
Other family in Scottsdale
- Kaitlyn LouchheimScottsdale$208K
- Jennifer PrinceScottsdale$76K
- Camilla BinksScottsdale$62K
- Jessica TapiaScottsdale$36K
- Dawn MougelScottsdale$34K
- Keegan RussellScottsdale$28K
- Jamie HowardScottsdale$14K
- Anna CramerScottsdale$14K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.